<DOC>
	<DOCNO>NCT00514683</DOCNO>
	<brief_summary>The general purpose trial investigate efficacy safety 4 dose strategy BIBF 1120 treatment 12 month , compare placebo patient idiopathic pulmonary fibrosis . The primary objective study demonstrate whether least one dose strategy superior placebo patient IPF , modify rate decline Forced Vital Capacity ( FVC ) . As secondary objective , additional parameter assess order differentiate dose strategy basis safety efficacy</brief_summary>
	<brief_title>Safety And Efficacy BIBF 1120 Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>1 . Patient &gt; 40 year 2 . Written inform consent sign prior entry study 3 . IPF diagnose ( accord ATS / ERS criterion ) less 5 year prior screen visit . 4 . HRCT within 12 month randomisation biopsy ( latter need fulfil ATS/ERS criterion ) centrally review consistent diagnosis . 5 . FVC &gt; 50 % predict value Predicted normal value calculate accord ESCS ( R941408 ) : Males : FVC predict ( L ) = 5.76 x height ( meter ) 0.026 x age ( year ) 4.34 Females : FVC predict ( L ) = 4.43 x height ( meter ) 0.026 x age ( year ) 2.89 6 . Single breath DLCO ( correct Hb ) 30 79 % inclusive predict . Different site may use different prediction formula , base method use measure DLco . In case , method use must compliance ATS/ERS guideline DLCO measurement ( R062002 ) , prediction formula appropriate method . Raw data ( gas mixture , equation use prediction normal , adjustment make ) must trace . Adjustment haemoglobin ( R062002 ) : Males : DLCO predict Hb = DLCO predict x ( 1.7Hb/ [ 10.22+Hb ] ) Females : DLCO predict Hb = DLCO predict x ( 1.7Hb/ [ 9.38+Hb ] ) Hb express g/dL1 7 . PaO2 &gt; = 55 mmHg ( sea level 1500 ) 50 mmHg ( 1500 ) room air 1 . AST , ALT &gt; 1.5 x ULN ; 2 . Bilirubin &gt; 1.5 x ULN 3 . Relevant airways obstruction 4 . Continuous oxygen supplementation randomisation ( define &gt; 15 hour supplemental oxygen per day ) . 5 . Active infection screen randomisation . 6 . Neutrophils &lt; 1500 / mm3 7. International normalise ratio ( INR ) &gt; 1.5 and/or Partial thromboplastin time ( PTT ) &gt; 1.5 x ULN ; 8 . Platelets &lt; 100 000 /mL 9 . Haemoglobin &lt; 9.0 g/dL 10 . In opinion Investigator , patient likely lung transplantation study 11 . Life expectancy disease IPF &lt; 2.5 year ( Investigator assessment ) . 12 . Other disease may interfere test procedure judgement Investigator may interfere trial participation may put patient risk participate trial . Myocardial infarction previous 6 month Unstable angina previous month 13 . Other investigational therapy receive within 8 week prior screen visit . 14 . Pregnant woman woman breast feed child bear potential use highly effective method birth control least one month prior enrolment . 15 . Sexually active male commit use condom course study ( except partner childbearing potential ) . 16 . Known suspect active alcohol drug abuse . 17 . Bleeding risk : Known inherited predisposition bleeding , patient require fulldose anticoagulation , Patients require fulldose antiplatelet therapy , History hemorrhagic CNS event within 12 month prior screen , Any follow within 3 month prior screen : Gross / frank haemoptysis haematuria , Active gastrointestinal bleeding ulcer , Major injury surgery 18 . Thrombotic risk 19 . Surgical procedure plan occur trial period . 20 . Coagulopathy 21 . Uncontrolled systemic arterial hypertension 22. know hypersensitivity lactose component study medication</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>